Deal snapshot: The German pain-management specialist is acquiring Valinor to gain additional geographic rights to the gastrointestinal drug Movantik and add to its US product portfolio.

On the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023.

Leaders from the companies explain how they navigated to success with the world’s first CRISPR-based medicine – and avoided the pitfalls that claimed other programs.

The gene-editing company has achieved proof-of-concept for its base-editing platform in three patients – but safety concerns have sent its share price into decline.